Skip to content

PharmacoMRI of Parkinson Disease

A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01528592
Enrollment
18
Registered
2012-02-08
Start date
2011-06-30
Completion date
2012-07-31
Last updated
2018-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Brief summary

Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in Parkinson's Disease patients will show greater effects on brain networks associated with motor control.

Detailed description

Subject participation includes two 25-30 minute MRI scans. The subject will arrive in the off state (PD medications withheld for approximately 12 hours prior to the scan). Following the initial scan, the subject will receive 125% of his or her usual daily morning dose of PD medications which is calculated as levodopa dose equivalents (LDE) and is given as carbidopa-levodopa. The subject will then wait for an hour allowing for the medication to begin working. During this time the subject will complete cognitive assessments, questionnaires regarding the history and current state of PD, and motor assessments. The subject will then undergo a second MRI scan of approximately 25-30 minutes. The subject after completing the second MRI scan is free to leave. The entire study is approximately 2 and 1/2 hours long.

Interventions

Equivalent amount of carbidopa-levodopa will be provide to you

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Idiopathic Parkinson's Disease (PD) * Older than 30 years of age at the time of diagnosis * Hoehn and Yahr stage greater than or equal to 2.5 * PD duration greater than 3 years * Stable regimen of PD medications for at least 2 weeks prior to imaging * PD medications include carbidopa-levodopa

Exclusion criteria

* Patients with a diagnosis of other neurodegenerative conditions * Patients unwilling or unable to give informed consent * Contraindications (cardiac pacemaker, etc.) or inability (e.g., claustrophobia) to undergo MRI scan

Design outcomes

Primary

MeasureTime frameDescription
Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex.1 hourCorrelation coefficient between UPDRS III score and independent components analysis network strength in left parietal cortex. UPDRS III is the Unified Parkinson's Disease Rating Scale composite motor score.

Countries

United States

Participant flow

Recruitment details

Recruitment period: 12/1/2011 - 4/30/2012 Location: Medical clinic in Chicago

Participants by arm

ArmCount
On / Off Medication
Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
18
Total18

Baseline characteristics

CharacteristicOn / Off Medication
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
7 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
Age, Continuous66.22 years
STANDARD_DEVIATION 8.71
Region of Enrollment
United States
18 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 18
serious
Total, serious adverse events
0 / 18

Outcome results

Primary

Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex.

Correlation coefficient between UPDRS III score and independent components analysis network strength in left parietal cortex. UPDRS III is the Unified Parkinson's Disease Rating Scale composite motor score.

Time frame: 1 hour

ArmMeasureValue (NUMBER)
On / Off MedicationCorrelation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex.0.5869 unitless

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026